Effective Gene Editing for Commercial Use with Cas-CLOVER

Simple commercial licenses and industry-leading CRISPR FTO meets efficiency, precision and outstanding know-how transfer.

Clean Gene Editing And Licensing With Cas-CLOVER-bnr-img

Efficiency

Generate targeted knockouts and knock-ins with equal or greater efficiency compared to Cas9

Accessible

A single license with Demeetra offers industry-leading Freedom to Operate (FTO) and favorable terms. Streamline your CRISPR due diligence process and proceed efficiently

Knowledge Transfer

Our gene editing experts internally validate processes and subsequently transfer this knowledge to you, ensuring seamless adoption

Demonstrated Efficiency in Key Commercial Systems

Cas-CLOVER generates targeted knockouts and knock-ins with high efficiency. We have demonstrated this across various systems in-house. By carefully crafting protocols, we ensure our clients receive the necessary knowledge to commence their projects promptly and effectively.

Cell lines
Greater than 90% editing efficiency in CHO-K1 cells
Plants
Successful targeting of albino phenotype gene in plants
Yeast & Microbes
Red colonies demonstrate high efficiency knock-ins

Explore Licensing

Larger deletions & improved knock-in efficiency

Clo051's nuclease activity results in staggered cuts leading to large deletions and improved knock-ins. Deletions ranging from 8 to 50 base pairs or more have been shown to cause complete disruption in gene expression. Publications on Cas9 indicate a knock-in limit of 7-10 kilobases, while Cas-CLOVER is capable of efficiently introducing at least 20 kilobases at a selected genomic site.

A chart showing the adjusted total protein area of several HEK-293 cell clones

Editing efficiency in HEK293 cells was 92.3%, with larger deletions causing full knockout.

Exceptional Precision

Cas-CLOVER requires Clo051 dimerization for its activity, leading to minimal off-target effects. In peer-reviewed publications, Cas-CLOVER exhibits a maximum potential off-target indel rate of less than 1%, whereas Cas9 can reach up to 10%.

Publications

Validated In Mammalian Cells, Yeast, and Plants

Our expertise and field of use spans multiple industries, allowing for the integration of Cas-CLOVER and transposase technologies into a wide range of commercial applications.